Cargando…
Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial
Static biomarkers like programmed death-ligand 1 (PD-L1) are insufficient to accurately predict response to immune checkpoint inhibition. Therefore, on-treatment biomarkers, which measure immediate therapy-associated changes, are currently shifting into the focus of immuno-oncology. A prime example...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121335/ https://www.ncbi.nlm.nih.gov/pubmed/37004206 http://dx.doi.org/10.1093/jncics/pkad027 |